ENDRA Life Sciences (NDRA) Stock Forecast, Price Target & Predictions
NDRA Stock Forecast
ENDRA Life Sciences stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
NDRA Analyst Ratings
According to 1 Wall Street analysts, ENDRA Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for NDRA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 08, 2022 | H.C. Wainwright | Buy | Buy | Hold |
ENDRA Life Sciences's last stock rating was published by H.C. Wainwright on Apr 08, 2022. The company gave NDRA a "Buy" rating, the same as its previous rate.
ENDRA Life Sciences Financial Forecast
ENDRA Life Sciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $300.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $700.00K | $225.00K |
| High Forecast | $300.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $700.00K | $225.00K |
| Low Forecast | $300.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $700.00K | $225.00K |
| # Analysts | - | - | - | - | 1 | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
ENDRA Life Sciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NDRA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
ENDRA Life Sciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | $-3.25M | $-3.05M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict NDRA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ENDRA Life Sciences's previous annual EBITDA (undefined) of $NaN.
ENDRA Life Sciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | $-3.27M | $-3.23M |
| Avg Forecast | $-23.34M | $-24.31M | $-24.31M | $-24.31M | $-19.23M | $-19.23M | $-37.82M | $-145.86M | $-486.21M | $-2.18B |
| High Forecast | $-23.34M | $-24.31M | $-24.31M | $-24.31M | $-19.23M | $-19.23M | $-37.82M | $-145.86M | $-486.21M | $-2.18B |
| Low Forecast | $-23.34M | $-24.31M | $-24.31M | $-24.31M | $-19.23M | $-19.23M | $-37.82M | $-145.86M | $-486.21M | $-2.18B |
| Surprise % | - | - | - | - | - | - | - | - | 0.01% | 0.00% |
ENDRA Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NDRA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ENDRA Life Sciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | $1.65M | $1.65M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
ENDRA Life Sciences's average Quarter SG&A projection for Mar 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to NDRA last annual SG&A of $1.65M (Dec 22).
ENDRA Life Sciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | $-1.09M | $-1.54 |
| Avg Forecast | $-2.16 | $-2.25 | $-2.25 | $-2.25 | $-1.78 | $-1.78 | $-3.50 | $-13.50 | $-45.00 | $-80.00 |
| High Forecast | $-2.16 | $-2.25 | $-2.25 | $-2.25 | $-1.78 | $-1.78 | $-3.50 | $-13.50 | $-45.00 | $-80.00 |
| Low Forecast | $-2.16 | $-2.25 | $-2.25 | $-2.25 | $-1.78 | $-1.78 | $-3.50 | $-13.50 | $-45.00 | $-80.00 |
| Surprise % | - | - | - | - | - | - | - | - | 24191.19% | 0.02% |
According to undefined Wall Street analysts, ENDRA Life Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NDRA previous annual EPS of $NaN (undefined).
ENDRA Life Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NDRA | ENDRA Life Sciences | $0.23 | $5.00 | 2073.91% | Buy |
| DRIO | DarioHealth | $0.87 | $10.75 | 1135.63% | Buy |
| STIM | Neuronetics | $0.95 | $8.00 | 742.11% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| BDSX | Biodesix | $1.80 | $3.00 | 66.67% | Buy |
| LAB | Standard BioTools | $2.00 | $3.25 | 62.50% | Buy |
| HTGM | HTG Molecular Diagnostics | $0.48 | $0.17 | -64.58% | Buy |
NDRA Forecast FAQ
Is ENDRA Life Sciences a good buy?
Yes, according to 1 Wall Street analysts, ENDRA Life Sciences (NDRA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of NDRA's total ratings.
What are ENDRA Life Sciences's analysts' financial forecasts?
ENDRA Life Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $400K (high $400K, low $400K), average EBITDA is $0 (high $0, low $0), average net income is $-222M (high $-222M, low $-222M), average SG&A $0 (high $0, low $0), and average EPS is $-20.56 (high $-20.56, low $-20.56). NDRA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $600K (high $600K, low $600K), average EBITDA is $0 (high $0, low $0), average net income is $-96.269M (high $-96.269M, low $-96.269M), average SG&A $0 (high $0, low $0), and average EPS is $-8.91 (high $-8.91, low $-8.91).